CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on enacyloxin IIa, an antibiotic with potential against resistant bacteria. It aims to explore the biosynthesis of this compound and develop stable analogues for further testing and potential clinical use.
Enacyloxin IIa is a polyketide antibiotic with activity against Gram-positive and Gram-negative bacteria that targets ribosomal elongation factor Tu.
It has recently been identified as metabolite of Burkholderia ambifaria AMMD and shown to have clinically-relevant activity against Acinetobacter baumannii, a problematic pan-resistant Gram-negative pathogen.
Despite its promising biological activity, enacyloxin IIa has not been used in the clinic, presumably due to stability issues.
Preliminary ex…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
